Charles Schwab Investment Management Inc. Has $2.59 Million Stock Holdings in argenx SE (NASDAQ:ARGX)

Charles Schwab Investment Management Inc. boosted its stake in argenx SE (NASDAQ:ARGX) by 21.8% in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 4,214 shares of the company’s stock after buying an additional 755 shares during the quarter. Charles Schwab Investment Management Inc.’s holdings in argenx were worth $2,592,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also modified their holdings of the company. Stifel Financial Corp boosted its position in argenx by 15.3% during the third quarter. Stifel Financial Corp now owns 8,832 shares of the company’s stock valued at $4,788,000 after purchasing an additional 1,170 shares during the last quarter. Stephens Inc. AR acquired a new stake in shares of argenx during the 4th quarter valued at about $310,000. Ritholtz Wealth Management lifted its holdings in shares of argenx by 85.5% during the 4th quarter. Ritholtz Wealth Management now owns 898 shares of the company’s stock valued at $552,000 after buying an additional 414 shares during the last quarter. MML Investors Services LLC grew its stake in shares of argenx by 16.9% in the 3rd quarter. MML Investors Services LLC now owns 8,699 shares of the company’s stock valued at $4,715,000 after buying an additional 1,255 shares in the last quarter. Finally, Wilmington Savings Fund Society FSB acquired a new position in argenx in the third quarter worth approximately $652,000. 60.32% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

ARGX has been the subject of several recent research reports. Piper Sandler boosted their target price on shares of argenx from $620.00 to $725.00 and gave the stock an “overweight” rating in a research report on Tuesday, January 7th. Robert W. Baird upped their price objective on shares of argenx from $650.00 to $680.00 and gave the stock a “neutral” rating in a report on Tuesday, March 4th. Wedbush reissued an “outperform” rating and set a $655.00 target price on shares of argenx in a research report on Tuesday, December 3rd. Oppenheimer boosted their price target on argenx from $675.00 to $704.00 and gave the stock an “outperform” rating in a research report on Friday, February 28th. Finally, Deutsche Bank Aktiengesellschaft raised argenx from a “sell” rating to a “hold” rating in a report on Wednesday, March 12th. Three research analysts have rated the stock with a hold rating, nineteen have issued a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $687.00.

argenx Price Performance

Shares of argenx stock opened at $593.47 on Friday. The company has a market cap of $36.06 billion, a PE ratio of -674.40 and a beta of 0.59. The firm has a fifty day moving average price of $629.28 and a two-hundred day moving average price of $600.95. argenx SE has a fifty-two week low of $352.77 and a fifty-two week high of $678.21.

argenx (NASDAQ:ARGX) last released its earnings results on Thursday, February 27th. The company reported $1.58 earnings per share for the quarter, beating the consensus estimate of $0.98 by $0.60. argenx had a negative net margin of 2.11% and a negative return on equity of 1.45%. The business had revenue of $761.22 million during the quarter, compared to analysts’ expectations of $678.52 million. Analysts expect that argenx SE will post 3.13 earnings per share for the current fiscal year.

argenx Profile

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren’s syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.